Episode 56: Thermo Fisher

This week on Petri Dish Perspectives, we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology.

From its origins in scientific instrumentation to becoming a global life sciences infrastructure giant, we explore how Thermo Fisher built an empire through acquisitions, genomics, diagnostics, contract manufacturing, and the “picks-and-shovels” strategy behind biotech’s biggest breakthroughs. We also unpack the company’s role during COVID-19, its expansion into CDMO services, and why some of the most powerful companies in healthcare are often the ones nobody talks about.

This is the story of the invisible engine behind modern biology and the company behind the companies.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#ThermoFisher #Biotech #LifeSciences #Biotechnology #Pharma #DrugDevelopment #Genomics #Diagnostics #CDMO #HealthcareInnovation #PrecisionMedicine #Science #Biopharma #PetriDishPerspectives #LaboratoryScience #SyntheticBiology #ThermoFisherScientific

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, a storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

When most people think about biotechnology, they think about miracle drugs. They think about blockbuster therapies, Nobel Prize-winning discoveries, and biotech CEOs ringing the NASDAQ bell after a successful IPO.

But behind every PCR test, every antibody therapy, every gene sequencing experiment, every CAR-T manufacturing process, and every COVID vaccine batch, there is another layer of the industry that almost nobody talks about.

The infrastructure layer. The freezers. The centrifuges. The chromatography systems. The reagents. The cell culture media. The sequencing consumables. The contract manufacturing plants. The logistics networks.

And sitting at the center of that global biological infrastructure is today’s company:

Thermo Fisher Scientific. This is the story of how a quiet laboratory equipment company became the operating system of modern biology.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

The Origins: From Thermometers to Biotechnology

To understand Thermo Fisher, you first have to understand that it wasn’t born as a biotech company. It was assembled.

The roots of the business trace back to two entirely separate corporate lineages:

• Thermo Electron
• Fisher Scientific

Thermo Electron was founded in 1956 by George Hatsopoulos, a Greek-American MIT engineer obsessed with thermodynamics and energy systems.

Originally, Thermo Electron focused on industrial technologies tied to heat transfer and energy conversion. But over time, the company realized that analytical instruments represented a much larger opportunity.

Scientific instruments had something powerful: Recurring demand.

Once a laboratory standardized around your systems, they continued buying:

• consumables
• maintenance contracts
• software
• replacement instruments

It was a razor-and-blade model for science.

Meanwhile, Fisher Scientific had much older roots dating back to 1902, when Chester Garfield Fisher founded the company to supply laboratory equipment and chemicals to researchers and industrial labs. Fisher became one of the most trusted laboratory supply distributors in North America. If Thermo built instruments, Fisher controlled distribution. That combination would eventually become extraordinarily powerful.

The 2006 Merger: Creating a Scientific Superpower

In 2006, Thermo Electron merged with Fisher Scientific in a deal valued at roughly $12.8 billion.

The merger created: Thermo Fisher Scientific.

At first glance, it looked like a standard corporate consolidation. In reality, it was the creation of a vertically integrated scientific infrastructure empire. The strategy was brilliant.

Thermo brought:

• analytical instruments
• mass spectrometry
• chromatography systems
• high-end scientific hardware

Fisher brought:

• laboratory distribution
• consumables
• customer relationships
• procurement networks

Together, they could now sell an entire laboratory ecosystem rather than individual products.

A biotech startup no longer needed five vendors. Thermo Fisher could provide nearly everything.

This “full-stack biology” strategy became the company’s defining competitive advantage.

Acquisitions as a Scientific Weapon

One of the most fascinating parts of Thermo Fisher’s story is how aggressively it used acquisitions as a strategic weapon.

Like Danaher Corporation, Thermo Fisher realized that life sciences infrastructure is highly fragmented.

Instead of betting on one breakthrough drug, they bought:

• technologies
• manufacturing systems
• diagnostics platforms
• reagent companies
• biologics infrastructure

Over two decades, Thermo Fisher became an acquisition machine.

Some of the most important acquisitions included:

Life Technologies (2014)

This was transformative.

Thermo Fisher acquired Life Technologies for roughly $13.6 billion.

Life Technologies itself was already a genomics powerhouse formed from the merger of Invitrogen and Applied Biosystems.

This acquisition gave Thermo:

• PCR dominance
• sequencing infrastructure
• gene analysis tools
• cell biology reagents
• synthetic biology capabilities

Suddenly, Thermo Fisher became deeply embedded in molecular biology itself.

If you ran a biology lab in the 2010s, there was an extremely high probability you were using Thermo products every single day.

Patheon (2017)

Then came one of the company’s most strategically important moves:

The acquisition of Patheon.

This pushed Thermo Fisher directly into CDMO territory: Contract Development and Manufacturing Organizations.

This meant Thermo wasn’t just helping scientists discover drugs anymore.

Now they could manufacture them too.

That changed everything.

Biotech startups increasingly realized they no longer needed to build billion-dollar factories themselves. They could outsource manufacturing to companies like Thermo Fisher.

This made Thermo a critical infrastructure provider for:

• biologics
• cell therapies
• gene therapies
• mRNA manufacturing

During the COVID era, this positioning became incredibly valuable.

The COVID Explosion: Becoming Essential Infrastructure

The COVID-19 pandemic fundamentally changed Thermo Fisher’s public visibility.

Suddenly, the world learned that diagnostics infrastructure mattered.

Thermo Fisher became deeply involved in:

• PCR testing
• reagent manufacturing
• viral sequencing
• vaccine manufacturing support
• supply chain logistics

Governments around the world relied on Thermo systems during the pandemic response.

The company manufactured:

• COVID diagnostic kits
• RNA extraction reagents
• laboratory plastics
• bioprocessing materials

And importantly: they supplied the companies making the vaccines.

While Moderna and BioNTech became household names, Thermo Fisher quietly made money supplying the ecosystem underneath them.

This is why infrastructure businesses are so powerful.

You don’t need one drug to win. You win no matter which drug succeeds.

The Core Business Model: Selling the Entire Biological Stack

What makes Thermo Fisher uniquely powerful is that it participates in almost every layer of modern biology.

Research Layer

• antibodies
• reagents
• pipettes
• centrifuges
• cell culture systems

Analytical Layer

• mass spectrometry
• chromatography
• electron microscopy

Genomics Layer

• PCR systems
• sequencing prep
• qPCR assays
• synthetic biology tools

Clinical Layer

• diagnostics
• pathology systems
• clinical testing

Manufacturing Layer

• biologics production
• fill-finish services
• viral vector manufacturing
• cell therapy support

Very few companies in biotech have this degree of ecosystem penetration.

Thermo Fisher essentially monetizes biology itself.

The Genomics Revolution

One of Thermo Fisher’s biggest strategic advantages was recognizing early that biology was becoming an information science.

As sequencing costs collapsed after the Human Genome Project, genomics exploded.

Thermo Fisher positioned itself as a critical supplier for:

• next-generation sequencing workflows
• PCR systems
• genomic analysis
• companion diagnostics

This also placed the company in direct competition with: Illumina.

But instead of trying to dominate sequencing hardware entirely, Thermo focused on becoming indispensable across the broader workflow.

That distinction mattered.

Illumina specialized in sequencing machines. Thermo specialized in scientific ecosystems.

Criticisms and Controversies

Despite its success, Thermo Fisher has faced criticism on several fronts.

1. Market Consolidation

Many scientists worry that the scientific tools industry has become too consolidated.

Companies like:

• Thermo Fisher
• Danaher
• Agilent

control enormous portions of laboratory infrastructure.

Critics argue this reduces:

• pricing competition
• supplier diversity
• innovation flexibility

For smaller biotech companies, switching vendors can become extremely difficult once workflows are standardized.

2. China and Surveillance Concerns

Thermo Fisher also faced controversy over sales of genetic and sequencing technologies in China.

Human rights groups criticized the company for allegedly supplying equipment used in surveillance programs involving genetic profiling.

In response, Thermo Fisher announced restrictions on certain sales in 2019.

The controversy highlighted a growing ethical question in biotechnology:

When scientific infrastructure becomes globally distributed, who controls how it is used?

3. Dependence on Biotech Cycles

Although Thermo is more stable than drug companies, it is still heavily tied to biotech funding cycles.

When venture capital slows:

• laboratory spending slows
• startup creation slows
• equipment purchases decline

The biotech downturn of 2022–2024 exposed this vulnerability, particularly in the company’s bioprocessing and COVID-related revenues.

Lessons from Thermo Fisher

Thermo Fisher teaches several profound lessons about the life sciences industry.

Lesson 1: Infrastructure Can Be More Powerful Than Products

Drug companies depend on binary outcomes. Infrastructure companies benefit from the entire ecosystem growing.

Thermo Fisher doesn’t need to predict which therapy wins.

It profits from the existence of biotech itself.

Lesson 2: Biology Is Becoming Industrialized

Thermo Fisher recognized early that biology was evolving from artisanal experimentation into industrial-scale engineering.

The future belonged to:

• automation
• reproducibility
• scalable manufacturing
• integrated workflows

They built for that future before most people saw it coming.

Lesson 3: The Best Business Models Sit Beneath the Hype

The companies making headlines often depend on invisible suppliers underneath them.

Thermo Fisher became one of the most powerful companies in biotech precisely because it avoided relying on blockbuster drugs.

Instead, it sold the infrastructure everyone else needed.

What’s Next: AI, Automation, and Biological Foundries

As of 2026, Thermo Fisher is now positioning itself for the next era of biology: AI-driven laboratory automation.

The company is investing heavily in:

• automated workflows
• cloud-connected instrumentation
• AI-assisted diagnostics
• robotic biology labs
• next-generation biologics manufacturing

The long-term vision is clear:

Biology is becoming programmable.

And Thermo Fisher wants to become the operating system powering that programmable biological economy.

They are increasingly moving toward a world where:

• experiments are automated
• laboratories are digitized
• manufacturing is continuous
• biology behaves more like software engineering

In many ways, Thermo Fisher is trying to industrialize biology the same way Amazon industrialized logistics.

Thermo Fisher Scientific (NYSE: TMO) is a global leader in life sciences solutions, analytical instruments, and laboratory services. The company currently trades near $452 per share, bringing its market capitalization to approximately $168 billion. Thermo Fisher Scientific employs approximately 125,000 people globally. The company maintains a massive workforce to support its life sciences research, laboratory supply, and diagnostic operations across more than 230 locations worldwide.

Outro: The Company Behind the Companies

The story of Thermo Fisher Scientific is not about one miracle drug or one scientific breakthrough.

It is about infrastructure.

It is about building the systems that allow modern biotechnology to exist at global scale.

From sequencing DNA to manufacturing biologics to powering academic research labs, Thermo Fisher became the connective tissue of the life sciences economy.

And that may ultimately be more powerful than discovering any single therapy.

Because while biotech companies rise and fall, the infrastructure layer remains.

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening. See you next Thursday. Good bye.

References

1. www.wikipedia.org
2. https://www.fiercepharma.com/ 
3. https://endpoints.news/ 
4. https://www.thermofisher.com/us/en/home.html